PMC:7073332 / 499-1189 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"47","span":{"begin":289,"end":294},"obj":"Species"},{"id":"48","span":{"begin":391,"end":400},"obj":"Species"},{"id":"49","span":{"begin":401,"end":411},"obj":"Species"},{"id":"50","span":{"begin":465,"end":473},"obj":"Species"},{"id":"51","span":{"begin":539,"end":548},"obj":"Species"},{"id":"52","span":{"begin":549,"end":559},"obj":"Species"},{"id":"53","span":{"begin":677,"end":685},"obj":"Species"},{"id":"59","span":{"begin":243,"end":247},"obj":"Species"},{"id":"60","span":{"begin":360,"end":364},"obj":"Species"}],"attributes":[{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"Tax:9606"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"Tax:2697049"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Tax:2697049"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"Tax:694009"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Tax:2697049"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:2697049"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"Tax:694009"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"Tax:694448"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"Tax:694448"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"nd reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Usi"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":295,"end":302},"obj":"Body_part"},{"id":"T2","span":{"begin":303,"end":310},"obj":"Body_part"},{"id":"T3","span":{"begin":371,"end":378},"obj":"Body_part"},{"id":"T4","span":{"begin":431,"end":441},"obj":"Body_part"},{"id":"T5","span":{"begin":527,"end":535},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma84116"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma82740"},{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"nd reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Usi"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":401,"end":409},"obj":"Disease"},{"id":"T7","span":{"begin":465,"end":473},"obj":"Disease"},{"id":"T8","span":{"begin":549,"end":557},"obj":"Disease"},{"id":"T9","span":{"begin":677,"end":685},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"nd reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Usi"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":149,"end":150},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":289,"end":302},"obj":"http://purl.obolibrary.org/obo/PR_000029067"}],"text":"nd reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Usi"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":39,"end":43},"obj":"Chemical"},{"id":"T6","span":{"begin":97,"end":111},"obj":"Chemical"},{"id":"T7","span":{"begin":97,"end":106},"obj":"Chemical"},{"id":"T8","span":{"begin":107,"end":111},"obj":"Chemical"},{"id":"T9","span":{"begin":186,"end":194},"obj":"Chemical"},{"id":"T10","span":{"begin":269,"end":273},"obj":"Chemical"},{"id":"T11","span":{"begin":295,"end":302},"obj":"Chemical"},{"id":"T12","span":{"begin":303,"end":310},"obj":"Chemical"},{"id":"T13","span":{"begin":431,"end":441},"obj":"Chemical"},{"id":"T14","span":{"begin":527,"end":535},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_36044"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_36976"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"nd reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Usi"}

{"project":"LitCovid-sentences","denotations":[{"id":"T6","span":{"begin":55,"end":331},"obj":"Sentence"},{"id":"T7","span":{"begin":332,"end":482},"obj":"Sentence"},{"id":"T8","span":{"begin":483,"end":686},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"nd reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Usi"}